ReviewCurrent cardiology reports2025
Innovating the Gold Standard: The Emerging Role of Echocardiographic Stress Testing in the Classification, Stratification, and Prognostication in Pulmonary Vascular Disease.
Review in Current cardiology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purpose of reviewThe goal of this review is to examine the evolving role of exercise stress echocardiography (ESE) in the diagnosis and management of pulmonary vascular diseases (PVD), particularly pulmonary hypertension (PH). We sought to explore how ESE can assess dynamic cardiopulmonary interactions, distinguish between PH subtypes, evaluate right ventricular (RV) contractile function and reserve, and provide a noninvasive alternative for early detection, risk stratification, and clinical decision-making in patients with unexplained dyspnea and PVD. RECENT
findingsAlthough right heart catheterization (RHC) remains the diagnostic gold standard, ESE has emerged as a promising noninvasive tool to assess dynamic changes in ventricular function, interventricular interactions, cardiopulmonary hemodynamics, and systemic circulation under stress conditions. Beyond traditional ischemic evaluation, ESE has demonstrated potential for identifying underlying causes of dyspnea in populations with rising cardiopulmonary risk factors such as aging, cardiovascular disease, obesity, COPD, and left heart failure. Recent studies highlight the ability of ESE to differentiate PH subtypes and offer prognostic insights. However, important knowledge gaps remain, particularly regarding standardized protocols and interpretation across different PH groups. Our review affirms that ESE offers a valuable, noninvasive approach for the early identification and risk stratification of PH, complementing or, in selected cases, providing an alternative to invasive hemodynamics. By evaluating dynamic cardiopulmonary interactions and RV reserve, ESE can refine diagnosis, improve clinical management, and potentially guide earlier therapeutic interventions in at-risk patients. Future research should focus on standardizing ESE methodologies, validating noninvasive surrogate measures of hemodynamics, and expanding its role in clinical practice to optimize the care of patients with PVD.
Indexed as
Identifiers
40550914What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.